Viridian aims to challenge Amgen in a blockbuster market, and it’s now tapped Chinese CDMO giant WuXi Biologics in a manufacturing pact. More: Viridian, awaiting FDA decision, taps WuXi Bio in eye drug supply deal Source: fierce
read moreIn another round of Big Pharma layoffs in New Jersey, Johnson & Johnson is dismissing 56 employees at its corporate headquarters in New Brunswick. The layoffs are part of the company’s effort to separate its orthopedics business. More: As J&J
read moreWith honor comes scrutiny. Ivonescimab’s plenary status means its Harmoni-6 results in first-line non-small cell lung cancer will be put under the microscope and critiqued carefully at the upcoming ASCO 2026 annual meeting. More: ASCO preview: With expectations jacked up,
read moreAmid a nearly $1 billion GLP-1 manufacturing expansion that began in 2024, CMDO CordenPharma is doubling down on its peptide capacity ambitions. More: GLP-1 manufacturer CordenPharma strikes deal for peptide CDMO, lining up new production sites in US and China
read moreAs regulatory, pricing and policy dynamics whipsaw in the United States, healthcare and life sciences firms are facing enormous pressures to keep profits rising, with those challenges now “becoming more acute by the quarter,” according to an inaugural industry distress
read more© 1994 - 2026 B.M. Pharmaceuticals